+

WO2003031628A1 - Polypeptides secretoires a activite sphingosine kinase et genes de sphingosine kinase codant pour ces polypeptides - Google Patents

Polypeptides secretoires a activite sphingosine kinase et genes de sphingosine kinase codant pour ces polypeptides Download PDF

Info

Publication number
WO2003031628A1
WO2003031628A1 PCT/JP2001/008538 JP0108538W WO03031628A1 WO 2003031628 A1 WO2003031628 A1 WO 2003031628A1 JP 0108538 W JP0108538 W JP 0108538W WO 03031628 A1 WO03031628 A1 WO 03031628A1
Authority
WO
WIPO (PCT)
Prior art keywords
sphingosine
sphingosine kinase
nucleic acid
acid molecule
related disease
Prior art date
Application number
PCT/JP2001/008538
Other languages
English (en)
Japanese (ja)
Inventor
Yasuyuki Igarashi
Akio Kihara
Original Assignee
Hokkaido Technology Licensing Office Co., Ltd.
Chemical Biology Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido Technology Licensing Office Co., Ltd., Chemical Biology Institute filed Critical Hokkaido Technology Licensing Office Co., Ltd.
Priority to PCT/JP2001/008538 priority Critical patent/WO2003031628A1/fr
Priority to JP2003534598A priority patent/JPWO2003031628A1/ja
Publication of WO2003031628A1 publication Critical patent/WO2003031628A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a secreted polypeptide having sphingosine kinase activity (SPHK activity) and a sphingosine kinase gene encoding the same, and particularly to human-derived secreted sphingosine kinase 3 (SPHK3) and It relates to the sphingosine kinase gene encoding.
  • SPHK activity sphingosine kinase activity
  • SPHK3 human-derived secreted sphingosine kinase 3
  • Sphingosine kinase is an enzyme that phosphorylates sphingosine and catalyzes the production of sphingosine 1-phosphate, which is mainly present in platelets.
  • Sphingosine 1-phosphate generated by phosphorylation of sphingosine, is accumulated in platelets in the blood and released with the activation of platelets.
  • This sphingosine: I-phosphate is known to have various physiological and pathological roles such as promotion of platelet aggregation, wound healing of blood vessel walls, anticancer metastasis, and prevention of arteriosclerosis.
  • SPHK1 sphingosine kinase 1
  • SPHK1 is a protein with a molecular weight of 43 kDa, and shows the strongest SPHK activity among conventionally known SPHKs. It is abundant in the cytoplasm and has high affinity for calmodulin. As a splicing variant, SPHK la
  • SPHK2 is a protein with a molecular weight of 65 kDa, and its SPHK activity is about 1/50 that of SPM1. Increases and inhibitions of activity were observed depending on the concentration of detergent, NaCl, and KC1. Dehydrosfingosine is a better substrate than sphingosine. In addition, mRNA expression is strongly expressed in kidney, liver and brain.
  • SPHK1 and SPHK2 are enzymes that catalyze the phosphorylation of sphingosine, but these have been shown to have intracellular effects, but have been found to produce extracellular sphingosine-1-phosphate. Not been. In other words, these enzymes were not enzymes responsible for the production of sphingosine-1-phosphate in blood, and were not suitable for drug development targeting SPHK in blood.
  • an object of the present invention is to provide a novel sphingosine kinase that controls the production of sphingosine-1-phosphate present in blood different from SPHK1 and SPHK2. Day S
  • the present inventors conducted intensive research to solve the above-mentioned problems, and found a novel secretory sphingosine kinase 3 (SPHK3) different from SPHK1 and SPHK2 by homology analysis of SPHK1 based on EST data.
  • SPHK3 novel secretory sphingosine kinase 3
  • the present invention relates to a secretory polypeptide having sphingosine kinase activity.
  • the present invention also relates to the secretory polypeptide, which is derived from human.
  • the present invention also relates to a sphingosine kinase gene encoding the above-mentioned polypeptide.
  • nucleic acid molecule (a) or (b).
  • nucleic acid molecule consisting of a nucleotide sequence that differs from the nucleotide sequence of SEQ ID NO: 2 due to the degeneracy of the genetic code, but encodes the same amino acid sequence as in (a).
  • the present invention also relates to a sphingosine kinase gene containing the above nucleic acid molecule.
  • the present invention relates to an expression vector comprising the sphingosine kinase gene operably linked to a promoter.
  • the present invention also relates to a sphingosine kinase-expressing host cell transformed or transfected using the above-described expression vector.
  • the present invention relates to a method for producing sphingosine kinase, which comprises culturing the host cell.
  • the present invention also relates to a method for detecting a sphingosine kinase gene, which comprises using the nucleic acid molecule and / or a nucleic acid molecule that hybridizes with the nucleic acid molecule under stringent conditions.
  • the present invention relates to a method for diagnosing a sphingosine-related disease, which comprises using the nucleic acid molecule and / or a nucleic acid molecule that hybridizes with the nucleic acid molecule under stringent conditions.
  • the present invention also relates to a medicament for treating a sphingosine-related disease, comprising the polypeptide having sphingosine kinase activity and a pharmaceutically acceptable carrier.
  • the present invention relates to a medicament for treating a sphingosine-related disease, comprising the nucleic acid molecule and a pharmaceutically acceptable carrier.
  • the present invention also relates to a medicament for treating a sphingosine-related disease, comprising the host cell and a pharmaceutically acceptable carrier.
  • the present invention relates to the use of the polypeptide having sphingosine kinase activity as a medicament for treating a sphingosine-related disease.
  • the present invention also relates to the use of the above-described nucleic acid molecule in a medicament for treating a sphingosine-related disease.
  • the present invention relates to use of the above-mentioned host cell in a medicament for treating a sphingosine-related disease.
  • the present invention also relates to a method for screening a medicament for treating a sphingosine kinase-related disease, which is a method for labeling sphingosine and a drug in a medium of a host cell that expresses sphingosine kinase 3.
  • the present invention relates to the above method, comprising adding a compound, quantifying labeled sphingosine 1-phosphate, and evaluating the effect of the compound on sphingosine kinase activity.
  • the present invention relates to a medicament for treating a sphingosine-related disease obtained by the above-mentioned screening method.
  • the secretory polypeptide having sphingosine kinase activity of the present invention is typically a polypeptide represented by the amino acid sequence shown in FIG. It is secreted extracellularly.
  • FIG. 1 shows the amino acid sequence of human-derived SPHK3 (hSPHK3) of the present invention.
  • FIG. 2 is a diagram showing an outline of pcDNA3-Flagl and its restriction enzyme map.
  • FIG. 3 is a diagram showing the results of Western blotting of SPHK3 transiently expressed in C0S7 cells.
  • FIG. 4 is a diagram showing spots of TLC showing SPHK activity of SPHK3 transiently expressed in C0S7 cells.
  • FIG. 5 is a graph showing the SPHK activity of SPHK3 transiently expressed in C0S7 cells.
  • FIG. 6 is a graph showing the pH dependence of SPHK activity of SPHK3.
  • FIG. 7 is a graph showing the substrate specificity of SPHK3. Day fl ⁇ ..
  • sphingosine kinase activity refers to an enzyme activity that phosphorylates sphingosine and catalyzes the production of sphingosine 1-phosphate.
  • Sphingosine kinase 1 SPHK1
  • SPHK2 sphingosine kinase 2
  • SPHK3 polypeptides having SPHK activity of the present invention are typically Is sphingosine kinase 3 (SPHK3; SEQ ID NO: 1).
  • Amino acid deletion refers to partial deletion of one or more amino acids from an arbitrary amino acid sequence.
  • amino acid substitution means that one or more amino acids are replaced with another amino acid in an arbitrary amino acid sequence.
  • addition of an amino acid means that one or more amino acids are added to an arbitrary amino acid sequence.
  • the polypeptide having the SPHK activity of the present invention includes a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 in which amino acids are deleted, substituted or added, as long as the polypeptide has the SPHK activity. It is.
  • the sphingosine kinase gene of the present invention is a gene that encodes a polypeptide having SPHK activity, and is typically a gene that encodes sphingosine kinase 3 consisting of the amino acid sequence of SEQ ID NO: 1. .
  • the gene encoding sphingosine kinase 3 is typically a gene consisting of a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 2.
  • the sphingosine kinase gene of the present invention has a codon sequence different from the nucleotide sequence of SEQ ID NO: 2 due to the degeneracy of the genetic code.
  • Nucleic acids that are the same Genes consisting of molecules are also included.
  • the genetic code is a base sequence having information for defining the amino acid sequence of the polypeptide.
  • the base sequence of the present invention includes DNA, RNA and cDNA sequences.
  • the degeneracy of the genetic code will be described.
  • a leucine residue can be encoded by codons CTA, CTC, CTG, CTT, TTA and TTG, and each of these six codons encodes a leucine residue. They are equivalent in purpose.
  • nucleotide sequences Such a relationship between amino acid residues and nucleotide sequences is well known to those skilled in the art.
  • a gene encoding one amino acid sequence can be composed of a plurality of base sequences. Includes nucleic acid molecules consisting of sequences.
  • the promoter that can be used in the present invention is not particularly limited as long as it can transcribe an operably linked nucleic acid molecule.
  • Specific promotions include CMV, SV40, PGK, EF321, MC1, TK, Plac, Pt ac, etc.
  • Ptac and Plac are preferred for expression in bacteria such as E. coli. From the viewpoint of the expression level, CMV and EF321 are preferred.
  • operably linked means that a regulatory sequence such as a promoter is directly or indirectly linked to a coding sequence such as a SPHK3 gene, and expression / transcription of a gene of the coding sequence is regulated by the Functionally linked so as to be under influence or control.
  • vector refers to a vector into which a desired sequence can be inserted by restriction enzyme treatment, ligation, or the like, for transfer between different gene environments or for expression in a host cell. is there.
  • RNA vectors typically consist of DNA, but RNA vectors are also available.
  • Vectors include, but are not limited to, plasmids, phagemids, and viral genomes.
  • Cloning vectors are capable of replication in a host cell, either autonomously or after integration into the genome of the host cell.
  • An expression vector is one in which a coding sequence is operably linked to a regulatory sequence so that the gene for the code sequence can be expressed as an RNA transcript.
  • a vector can include one or more marker sequences suitable for use in identifying whether a cell has been transformed or transfected with the vector.
  • Markers include, for example, genes encoding proteins that increase or decrease resistance or sensitivity to antibodies or other compounds (eg, kanamycin resistance gene, ampicillin resistance gene, etc.), and activity detected by standard methods Genes encoding possible enzymes (eg, monogalactosidase, alkaline phosphatase, luciferase, etc.) and phenotypes of transformed or transfected cells, hosts, colonies or plaques (eg, green fluorescent protein) (GFP), etc.).
  • GFP green fluorescent protein
  • Examples of such vectors include pBlueScriptl l SK (+), pB lueScript l I SK (-), pcDNA3-FLAGl, pcDNA3-HAl, pEGFP-N pEGFP-C pcDNA, etc.
  • Can be Examples of expression vectors include pGEX-2T and pMA and C2. Among them, pcDNA3-FLAGl and pMAL-C2 are preferred from the viewpoints of expression efficiency, recovery rate after expression, detection efficiency, solubilization of the expressed protein, and the like.
  • anti-FLAG M2 antibody preferred examples include anti-FLAG M2 antibody, anti-FLAG M5 antibody, and GFP.
  • "Stringent conditions” refers to nucleic acid hybridases that are commonly known.
  • a probe labeled with an appropriate marker is prepared from the nucleotide sequence represented by SEQ ID NO: 2, and the probe is hybridized with a nucleic acid obtained from a sample. This can be done. Such hybridization can also be used in a method for diagnosing a sphingosine-related disease.
  • the host cell used in the present invention may be any of prokaryotic cells and eukaryotic cells as long as sphingosine kinase 3 can be expressed, and is not particularly limited.
  • any cells such as animal cells, plant cells, filamentous fungi, and bacteria may be used. More specifically, COS 7, HEK293, HeLa, CH0, H.end FB, Jurkat, EG-OK CMK and the like can be mentioned.
  • Particularly preferred cells are C0S7 and HeLa, from the viewpoint of high expression level when transfused and production of endogenous SPHK3.
  • DMEM Dulbecco's modified Eagle's medium
  • a sphingosine-related disease is defined as Diseases / disorders caused by excessive, insufficient or defective phosphorylation. Also included are diseases caused by causes other than excess, deficiency or deficiency of sphingosine phosphorylation, which can be cured by regulating sphingosine phosphorylation.
  • sphingosine-related diseases include arteriosclerosis, cancer, allergy, and myocardial infarction.
  • the medicament of the present invention can be used as a therapeutic agent for sphingosine-related diseases. Further, it can be used as an angiogenesis promoter, an anti-cancer metastasis agent, an arteriosclerosis inhibitor and the like.
  • an active ingredient of the medicament of the present invention is an active ingredient of the medicament of the present invention.
  • a secretory sphingosine kinase such as SPHK3, a nucleic acid molecule encoding the same, or a host cell expressing the secretory sphingosine kinase can be used.
  • a pharmaceutically acceptable carrier refers to a carrier in which the polypeptides, nucleic acid molecules and host cells of the present invention are stably maintained, enable pharmaceutically effective administration, and are substantially non-toxic.
  • Means Specific carriers include water, serine, mineral oil, vegetable oils, animal oils, organic or inorganic oils, xanthan, gelatin, natural polymers such as cellulose or gum arabic, synthetic polymers, alcohols and the like.
  • the medicament of the present invention can be administered in a dosage form such as oral administration, intravenous administration, subcutaneous administration, intramuscular administration, and the like.
  • the dosage form can be appropriately selected according to the dosage form.
  • dosage forms suitable for oral administration such as powders, granules, pellets or tablets, coatings, capsules, solutions, syrups, etc., or injections, drops, suppositories, eye drops, nose drops, sprays It can be made into a dosage form suitable for parenteral administration.
  • These preparations can be prepared using known adjuvants usually used in the technical field of pharmaceutical preparations. Examples of the adjuvant include an excipient, a binder, a disintegrant, a lubricant, a flavoring agent, a solubilizing agent, a suspending agent, a coating agent and the like.
  • the dosage of these pharmaceutical preparations varies depending on symptoms, age, body weight, administration method, dosage form, etc. 0 mg, with a lower limit of lmg to 2 mg, with a preferred dosage of 5 mg.
  • the method for screening a medicament for treating a sphingosine kinase-related disease of the present invention includes, for example, preparing a SPHK-specific antibody from the amino acid sequence of the polypeptide shown in SEQ ID NO: 1, This can be done by Western blotting, immunoprecipitation, etc. using antibodies.
  • a specific labeled probe for SPHK can be prepared from the nucleotide sequence shown in SEQ ID NO: 2, and the sample can be subjected to Northern blot or the like.
  • the drugs obtained by these methods are further selected in an in vitro system based on desired properties (for example, properties inhibiting SPHK activity) as an index, and then examined for various diseases through animal experiments. Drugs having desired properties can be screened.
  • the following method is exemplified.
  • Sufi In coral screening thin kinase activity inhibitor, media play me 3 H of SP HK3 expressing cells - to quantify the sphingosine 1-phosphate by TLC or HPLC - was added sphingosine, 3 H to be generated in the medium.
  • a compound that is a candidate for an inhibitor can be added to the medium, and a compound having an inhibitory effect can be screened based on the level of the activity.
  • Labeling of Sufui Ngoshin is not limited to by 3 H, if also the become labeled, can be selected as appropriate, in the case of using the antibodies, it is possible to quantify the activity by using Imunoatsusi.
  • Inhibitors obtained by such screening can control the production of excess sphingosine triphosphate in the blood, such as platelet transfusion toxicity inhibitor, platelet stabilizer, etc. Can be used.
  • nucleotide sequence of the 0 E ST clone purchased from ATCC (American Type Culture Collection (http://www.atcc.org) for the clone 531456 homologous to this mSPHKl gene is only partially disclosed. Therefore, to determine the open reading frame (0RF) of the homologous clone, the entire nucleotide sequence of the EST clone was determined. From the estimated molecular weight of the polypeptide, we found 0RF, which is estimated to encode the target polypeptide.
  • FIG. 1 shows the amino acid sequence of the polypeptide encoded by the 0RF. This amino acid sequence is obtained from the signal sequence and its sequence by the prediction program of http: ⁇ www.cbs.dtu.dk / servers / SignalP-2.0 / (provided by Center for Biological Sequence Analysis, BioCentrum-DTU, Technica 1 University of Denmark). A cleavage site was expected.
  • Primer 1 (SEQ ID NO: 3):
  • Primer 2 (SEQ ID NO: 4):
  • the PCR reaction was performed using KOD dash (Toyobo) according to the manufacturer's protocol, using the cDNA prepared from clone AA075971 as a template, and using primers 1 and 2.
  • the reaction mixture was 2.5 U / / 1 K0D dash (1 ⁇ 1), 2 mM dNTP mix (5 ⁇ 1), 25 mM magnesium chloride (2 ⁇ 1), and 10X reaction buffer (5 ⁇ 1). ⁇ 1.
  • the PCR reaction was performed 25 cycles, each cycle consisting of 98 ° C for 15 seconds, 65 ° C for 2 seconds and 74 ° C for 30 seconds.
  • the obtained PCR product was confirmed by agarose gel electrophoresis, it was a fragment of about 1300 bp.
  • the nucleotide sequence was determined by a conventional method (SEQ ID NO: 2).
  • the resulting PCR product was digested with BamHI and EcoRI, and the transcript was digested with BamHI and EcoRI so that the transcript had a FLAG HA tag at the N-terminus.
  • pcDNA3-FLAG1 purchased pcDNA3 from Invitrogen, It was prepared by inserting the FLAG expression sequence at the MAP position, and was incorporated into Figure 2).
  • Glue medium (DMEM (Dulbecco, modified Eagle's mudium, purchased from SIGMA) with 10% fetal serum, lOU / ml penicillin, 100 ⁇ g / ml streptomycin) at 37 ° C, 5% It was carried out in the C0 2 conditions.
  • DMEM Dulbecco, modified Eagle's mudium, purchased from SIGMA
  • C0S7 cells were collected using 13 ⁇ 4-mercaptoethanol). Collect The protein was separated by SDS-PAGE using a 1/10 amount of the cultured cells as a sample by a conventional method. The separated protein is applied to a polyvinylidene difluoride membrane (I).
  • SPHK3 has a signal sequence (underlined in Fig. 1) at the N-terminus, which is cleaved at the cleavage site shown in Fig. 1 in the endoplasmic reticulum (ER) to convert from immature to mature .
  • the precipitate is collected, and an Assay buffer containing 0.01% TritonX-100, 50 M sphingosine, ImM [r-32P] ATP (composition: 15 mM MOPS, ImM phenylmethylsulfonyl fluoride, 50 mM NaCl, 5 mM mM M sodium orthovanadate, 2 mM MgCl 2 , ImM 4-deoxypyridoxin, ImM EDTA, 0.5% aprotinin, pH 7.5) were added and incubated at 37 ° C. for 30 minutes. Then, the method of Olivera et al.
  • Figure 4 shows spots of TLC, but sphingosine 1-1, which is hardly found in the control (pcDNA3-FLAG1 alone) from cells transfected with pcDNA3-Flagl into which the hSPHK3 gene has been inserted. Phosphoric acid spots (positions indicated by arrows in the figure) clearly appeared, confirming that the inserted polypeptide encoded by the hSPHK3 gene had SPHK activity.
  • Fig. 5 is a graph of the spots in Fig. 4 quantified.It can be seen that the cells transfected with PCDNA3-Flagl into which the hSPHK3 gene was inserted have 63 times higher SPHK activity than the control. Was.
  • SPHK3 has an optimum pH around neutrality, especially around pH 6.5-8.
  • kinase activity was measured using a lipid other than sphingosine as a substrate.
  • the measuring method is the same as in Example 3.
  • the lipids used (10 ⁇ g each) were D-erythro- sphingosine (SPH), D-erythro-dihydrosphingosine (DHS), N, N_ Dimethyl sphingosine (N, N-dimethyl l-sphingosine (DMS)), ceramide (ceramide (CER)), C2-ceramide (C2-Ceramide (C2-CER)) (Matreya), diacilglycerol (diacylgly cerol (DG)) (Avanti) and phosphatidylinositol (PI) (SIGMA).
  • Fig. 7 shows the results.
  • hSPH has the strongest activity on sphingosine, but also has activity on DHS, DMS, DG and PI. ⁇ ⁇ ilffl calf
  • SPHK3 novel sphingosine kinase 3 (SPHK3) different from SPHK1 and SPHK2 was obtained from the EST database.
  • SPHK 3 has SPHK activity and can be used as a medicament for treating sphingosine-related diseases.
  • the SPHK3 of the present invention and the SPHK3 gene can be applied to diagnosis of a sphingosine-related disease and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des polypeptides sécrétoires possédant une activité sphingosine kinase . Elle concerne, en particulier, une sphingosine kinase 3 d'origine humaine (SPHK3) et un gène de sphingosine kinase la codant.
PCT/JP2001/008538 2001-09-28 2001-09-28 Polypeptides secretoires a activite sphingosine kinase et genes de sphingosine kinase codant pour ces polypeptides WO2003031628A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/JP2001/008538 WO2003031628A1 (fr) 2001-09-28 2001-09-28 Polypeptides secretoires a activite sphingosine kinase et genes de sphingosine kinase codant pour ces polypeptides
JP2003534598A JPWO2003031628A1 (ja) 2001-09-28 2001-09-28 スフィンゴシンキナーゼ活性を有する分泌型ポリペプチドおよびそれをコードするスフィンゴシンキナーゼ遺伝子

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2001/008538 WO2003031628A1 (fr) 2001-09-28 2001-09-28 Polypeptides secretoires a activite sphingosine kinase et genes de sphingosine kinase codant pour ces polypeptides

Publications (1)

Publication Number Publication Date
WO2003031628A1 true WO2003031628A1 (fr) 2003-04-17

Family

ID=11737776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008538 WO2003031628A1 (fr) 2001-09-28 2001-09-28 Polypeptides secretoires a activite sphingosine kinase et genes de sphingosine kinase codant pour ces polypeptides

Country Status (2)

Country Link
JP (1) JPWO2003031628A1 (fr)
WO (1) WO2003031628A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005365A1 (fr) * 1998-07-22 2000-02-03 Smithkline Beecham P.L.C. Lcb kinase 1 humaine
WO2000052173A2 (fr) * 1999-03-02 2000-09-08 Nps Allelix Corp. Homologues de sphingosine kinase humaine clones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005365A1 (fr) * 1998-07-22 2000-02-03 Smithkline Beecham P.L.C. Lcb kinase 1 humaine
WO2000052173A2 (fr) * 1999-03-02 2000-09-08 Nps Allelix Corp. Homologues de sphingosine kinase humaine clones

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HONG LIU ET AL.: "Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 26, June 2000 (2000-06-01), pages 19513 - 19520, XP002949759 *
TAKAFUMI KOHAMA ET AL.: "Molecular cloning and functional characterization of murine sphingosine kinase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 37, September 1998 (1998-09-01), pages 23722 - 23728, XP002949758 *

Also Published As

Publication number Publication date
JPWO2003031628A1 (ja) 2005-01-27

Similar Documents

Publication Publication Date Title
JP3193301B2 (ja) 生理活性タンパク質ｐ１６０
US5906819A (en) Rho target protein Rho-kinase
JP3991327B2 (ja) 甲状腺組織試料中の甲状腺癌細胞を検出する方法及び甲状腺癌の組織診断用組成物
Mao et al. Cloning and characterization of a mouse endoplasmic reticulum alkaline ceramidase: an enzyme that preferentially regulates metabolism of very long chain ceramides
US20070202520A1 (en) Novel lipase
JP2001521400A (ja) ケラチノサイト由来カリクレイン
WO1999067384A2 (fr) Genes associes au cancer de la prostate
Liu et al. GBPI, a novel gastrointestinal-and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA
US6187559B1 (en) Phospholipase D gene
JP2002505842A (ja) 延長因子２キナーゼ（ｅｆ−２キナーゼ）およびその使用方法
US5786150A (en) F0 ATP synthase subunit
US20030175923A1 (en) Human transferase proteins
WO2003031628A1 (fr) Polypeptides secretoires a activite sphingosine kinase et genes de sphingosine kinase codant pour ces polypeptides
KR20010085373A (ko) 포유류 말로닐 ＣｏＡ 데카복실라아제 억제제, 효능제 및길항제를 동정하기 위한 조성물 및 방법
JP2003527824A (ja) ポリペプチドおよび核酸をシグナリングする新規細胞
PT914451E (pt) Quinase activada por il-1/tnf-x (itak) e métodos para produzifr e utilizar a mesma
US5474921A (en) Expression and purification of phosphoinositide-specific phospholipase C-γ
US7060456B2 (en) Regulation of human protein phosphatase IIc-like enzyme
JP2003189883A (ja) 新規ユビキチン特異プロテアーゼ
WO2003031627A1 (fr) Polypeptides a origine plaquettaire a activite sphingosine kinase et genes de sphingosine kinase codant pour ces polypeptides
JP3647856B2 (ja) 哺乳動物の造血器型プロスタグランジンｄ合成酵素をコードするｄｎａ
JP4975031B2 (ja) 薬物リン酸化酵素
JPH10201479A (ja) フォスフォリパーゼａ１ 及びそれをコードする核酸
US20060099681A1 (en) Human and mouse alkaline ceramidase 1 and skin diseases
JP2003199588A (ja) 新規ユビキチン特異プロテアーゼ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ PL PT RO RU SD SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003534598

Country of ref document: JP

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载